Ad-RTS-hIL-12
AXP000146.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, RheoSwitch-regulated)
- Targets
- IL12A; IL12B
- Originator
- Ziopharm Oncology
- Sponsor
- Alaunos Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| Ad-RTS-hIL-12 | preferred name, code | curator, ncit |
| INXN-2001 | code | ncit |
| Ad-RTS-hIL-12 + veledimex ambiguous | synonym | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- non-replicating adenoviral vector; human IL-12 p70 under RheoSwitch Therapeutic System control, induced by oral veledimex
- Transgenes
- IL12A, IL12B
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C143953
Approvals
No regulatory approval recorded.
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | Terminated | Phase 2 | 2019-08-01 | 2021-08-05 | 40 | Glioblastoma |
| NCT03679754 | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | Completed | Phase 1 | 2018-09-05 | 2019-04-02 | 36 | Glioblastoma |
| NCT03636477 | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | Completed | Phase 1 | 2018-06-18 | 2020-10-15 | 21 | Glioblastoma |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | Terminated | Phase 1/2 | 2017-09-26 | 2021-09-10 | 6 | Diffuse Intrinsic Pontine Glioma; Pediatric Brain Tumor |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | Terminated | Phase 1/2 | 2015-07-18 | 2016-07-19 | 9 | Metastatic Breast Cancer |
| NCT02026271 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Completed | Phase 1 | 2015-06 | 2019-08 | 40 | Anaplastic Oligoastrocytoma; Glioblastoma Multiforme |
| NCT01703754 | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | Terminated | Phase 2 | 2013-04-04 | 2014-08-07 | 12 | Breast Cancer Nos Metastatic Recurrent |
| NCT01397708 | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma | Completed | Phase 1/2 | 2011-08 | 2014-09 | 26 | Melanoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34850166 | Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. | Neuro-oncology | 2022 | cited by trial NCT03636477 |
| PMID 31413142 | Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. | Science translational medicine | 2019 | cited by trial NCT02026271 |
Notes
Intratumoral adenovirus carrying human IL-12 under the RheoSwitch Therapeutic System, switched on by the oral activator ligand veledimex (a separate agent). Phase 1/2 in recurrent glioblastoma and in breast cancer; INXN-2001 is the Intrexon code. The related product INXN-3001 (NCIt C101789) is autologous dendritic cells transduced with the same switch and is a different program, not entered here.
How to cite
Ad-RTS-hIL-12 (AXP000146.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000146.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.